Sergio Jaramillo, MD
Sleep Medicine · Miami, FLNPI 1679770879
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $22,820 of the $31,807 with a category attached, or 71.7%. 60 manufacturers reported payments, led by AbbVie at 25.0% of the total. Among sleep medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,027 payments — averaging $30.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- UCB, Inc.$4K
- Pfizer$2K
- Abbott$2K
- Inspire Medical Systems, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $14K from 54 others
Across 141 payments — averaging $1340.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$106K
- Jazz Pharmaceuticals Inc.$65K
- E.r. Squibb & Sons, L.L.C.$14K
- Alkermes, Inc.$4K
What the payments were for
- Speaking & faculty fees$6,45820%
- Travel & lodging$1,8116%
- Food & beverage$22,82072%
- Education$7182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,807 in reported general payments places this provider in the 90th percentile of 77 sleep medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 47 | $231,834 |
| GocovriAmantadine Hcl | 71 | $180,508 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 36 | $115,222 |
| IngrezzaValbenazine Tosylate | 13 | $105,779 |
| NeuproRotigotine | 70 | $83,857 |
| RexultiBrexpiprazole | 26 | $46,680 |
| NourianzIstradefylline | 20 | $38,607 |
| Rasagiline Mesylate | 119 | $25,185 |
| RytaryCarbidopa/Levodopa | 30 | $24,460 |
| Nurtec OdtRimegepant Sulfate | 14 | $19,823 |
| NamzaricMemantine Hcl/Donepezil Hcl | 23 | $14,945 |
| TrintellixVortioxetine Hydrobromide | 26 | $12,480 |
| Entacapone | 42 | $10,778 |
| Memantine Hcl ErMemantine Hcl | 88 | $10,574 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 267 | $8,805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $77 | $231,83447 claims |
| MDD US Operations, LLCGocovri | $310 | $180,50871 claims |
| Grifols USA, LLCGamunex-C | $83 | $115,22236 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,073 | $105,77913 claims |
| UCB, Inc.Neupro | $4,014 | $83,85770 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $306 | $46,68026 claims |
| Kyowa Kirin, Inc.Nourianz | $70 | $38,60720 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $175 | $26,25748 claims |
| PfizerNurtec Odt | $1,675 | $19,82314 claims |
| AbbVieNamzaric | $7,950 | $14,94523 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $94 | $12,48026 claims |
| Eisai Inc.Dayvigo | $938 | $4,97614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 77 sleep medicine providers in Florida.
Other sleep medicine in Miami
- Edward MezerhaneMiami$537K
- Carlos Ramirez MejiaMiami$25K
- Harneet WaliaMiami$19K
- Alberto RamosMiami$8K
- Rosa GarciaMiami$3K
- Ghaith ShukriMiami$2K
- Salim DibMiami$2K
- Dionne MorganMiami$797
- Jeremy McConnellBradenton$615K
- Shane DrahosWinter Garden$317K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.